-
公开(公告)号：US12274699B2
公开(公告)日：2025-04-15
申请号：US18346029
申请日：2023-06-30
Applicant: Foundation Medicine, Inc.
Inventor： Siraj Mahamed Ali , Matthew J. Hawryluk , Jie He , Doron Lipson , Vincent A. Miller , Jeffrey S. Ross , Philip James Stephens
IPC: A61K31/517 , A61K31/19 , A61K31/404 , A61K31/435 , A61K31/4412 , A61K31/4439 , A61K31/47 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/53 , A61K31/5383 , A61K31/553 , A61K45/06 , C07K14/705 , C07K14/71 , C07K16/40 , C12N9/12 , C12N15/113 , C12Q1/6883 , C12Q1/6886 , G01N33/573
Abstract: Methods and compositions for treating cholangiocarcinoma.
-
公开(公告)号：US20160145691A1
公开(公告)日：2016-05-26
申请号：US14753397
申请日：2015-06-29
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: C12Q1/68 , A61K45/06 , C07K16/28 , C07K14/72 , A61K31/5415 , A61K31/437 , A61K31/423 , A61K31/428 , A61K31/472 , A61K31/536 , A61K31/416 , A61K31/4439
CPC classification number: C12Q1/6886 , A61K31/416 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/436 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K31/565 , A61K31/567 , A61K31/675 , A61K45/06 , C07K14/72 , C07K16/2869 , C07K2317/34 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
Abstract translation: 公开了新型突变体ESR1分子和用途。
-
公开(公告)号：US10980804B2
公开(公告)日：2021-04-20
申请号：US14761518
申请日：2014-01-17
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Siraj Mahamed Ali , Matthew J. Hawryluk , Jie He , Doron Lipson , Vincent A. Miller , Jeffrey S. Ross , Philip James Stephens
IPC: A61K31/517 , A61K31/498 , A61K31/19 , A61K31/5025 , C12N9/12 , A61K31/4412 , A61K45/06 , A61K31/47 , A61K31/435 , A61K31/506 , A61K31/519 , A61K31/4439 , A61K31/53 , A61K31/404 , A61K31/5383 , A61K31/496 , C12Q1/6886 , A61K31/553 , C07K14/705 , C07K14/71 , C07K16/40 , C12N15/113 , C12Q1/6883 , G01N33/573
Abstract: Methods and compositions for treating cholangiocarcinoma.
-
公开(公告)号：US20200211679A1
公开(公告)日：2020-07-02
申请号：US16579496
申请日：2019-09-23
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Michael Pellini , Gary Palmer , Mary Patricia Lancelotta , Matthew J. Hawryluk , Vincent A. Miller
Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment for the current patient.
-
公开(公告)号：US20170016073A1
公开(公告)日：2017-01-19
申请号：US15018640
申请日：2016-02-08
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: C12Q1/68 , A61K31/436 , A61K31/4196 , A61K31/567 , A61K45/06
CPC classification number: C12Q1/6886 , A61K31/416 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/436 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K31/565 , A61K31/567 , A61K31/675 , A61K45/06 , C07K14/72 , C07K16/2869 , C07K2317/34 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
Abstract translation: 公开了新型突变体ESR1分子和用途。
-
Patent Agency Ranking
公开(公告)号：US11725247B2
公开(公告)日：2023-08-15
申请号：US16080421
申请日：2017-02-27
Applicant: FOUNDATION MEDICINE, INC. , VANDERBILT UNIVERSITY
Inventor： Garrett Michael Frampton , Roman Yelensky , James Xin Sun , Douglas Buckner Johnson , Christine Marie Lovly , Jeffrey Alan Sosman , David Fabrizio , Philip James Stephens , Vincent A. Miller
CPC classification number: C12Q1/6886 , A61P35/00 , C07K16/2818 , G06F17/15 , G16B20/00 , G16H50/20 , G16H50/30 , A61K2039/505 , C12Q2600/106 , C12Q2600/156
Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.
-
公开(公告)号：US11286532B2
公开(公告)日：2022-03-29
申请号：US15877035
申请日：2018-01-22
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: C12Q1/6886 , A61K31/565 , A61K31/4196 , A61K31/675 , A61K31/439 , A61K31/567 , A61K31/416 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K45/06 , C07K14/72 , C07K16/28 , A61K31/436
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
-
公开(公告)号：US20200299775A1
公开(公告)日：2020-09-24
申请号：US16683575
申请日：2019-11-14
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Matthew J. Hawryluk , Doron Lipson , Vincent A. Miller , Philip James Stephens
IPC: C12Q1/6886 , C12N15/113 , C12N9/12 , C07K14/47 , A61K31/519 , A61K31/553 , A61K45/06
Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.
-
公开(公告)号：US20150073036A1
公开(公告)日：2015-03-12
申请号：US14473508
申请日：2014-08-29
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Matthew J. Hawryluk , Doron Lipson , Vincent A. Miller , Philip James Stephens
IPC: C12Q1/68 , A61K45/06 , C12N15/113 , A61K31/553 , A61K31/519
CPC classification number: C12Q1/6886 , A61K31/519 , A61K31/553 , A61K45/06 , C07K14/47 , C12N9/12 , C12N15/1138 , C12N2310/14 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158
Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.
Abstract translation: 公开了用于评估，鉴定，评估和/或治疗患有癌症的受试者的新型NTRK1融合分子，检测试剂和用途和试剂盒。
-
公开(公告)号：US12087453B2
公开(公告)日：2024-09-10
申请号：US17885412
申请日：2022-08-10
Applicant: Foundation Medicine, Inc.
Inventor： Michael Pellini , Gary Palmer , Mary Patricia Lancelotta , Matthew J. Hawryluk , Vincent A. Miller
CPC classification number: G16H70/60 , G16B30/00 , G16H10/20 , G16H10/60 , G16H15/00 , G16H20/10 , G16H50/20
Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.021 seconds)
